Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR. Balanescu AR, et al. Among authors: wolfram g. Ann Rheum Dis. 2014 Sep;73(9):1665-72. doi: 10.1136/annrheumdis-2012-203164. Epub 2013 Jul 12. Ann Rheum Dis. 2014. PMID: 23852695 Clinical Trial.
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.
Rauck RL, Hale ME, Bass A, Bramson C, Pixton G, Wilson JG, Setnik B, Meisner P, Sommerville KW, Malhotra BK, Wolfram G. Rauck RL, et al. Among authors: wolfram g. Pain. 2015 Sep;156(9):1660-1669. doi: 10.1097/j.pain.0000000000000230. Pain. 2015. PMID: 25993547 Clinical Trial.
Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B, Bass A, Bramson C, Levy-Cooperman N, Malhotra B, Matschke K, Geoffroy P, Sommerville KW, Wolfram G. Setnik B, et al. Among authors: wolfram g. Pain Med. 2017 Jun 1;18(6):1077-1088. doi: 10.1093/pm/pnw178. Pain Med. 2017. PMID: 27550954 Free PMC article. Clinical Trial.
Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P. Setnik B, et al. Among authors: wolfram g. J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2. J Clin Pharmacol. 2015. PMID: 26011742 Clinical Trial.
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
Weil AJ, Masters ET, Barsdorf AI, Bass A, Pixton G, Wilson JG, Wolfram G. Weil AJ, et al. Among authors: wolfram g. Health Qual Life Outcomes. 2017 Oct 17;15(1):202. doi: 10.1186/s12955-017-0749-y. Health Qual Life Outcomes. 2017. PMID: 29041942 Free PMC article. Clinical Trial.
329 results